HCV and tumor-initiating stem-like cells

Area of Science:

• Oncology
• Virology
• Stem Cell Biology

Background:

• Neoplasms, including hepatocellular carcinoma (HCC), harbor tumor-initiating cells (TICs) exhibiting enhanced drug resistance.
• Hepatocellular carcinoma (HCC) incidence is rising, necessitating a deeper understanding of its development and therapeutic resistance mechanisms.
• Hepatitis C virus (HCV) infection is a significant risk factor for HCC development.

Purpose of the Study:

• To review the intricate links between HCV-associated HCC and TICs.
• To elucidate how HCV contributes to TIC genesis and HCC progression.
• To identify novel therapeutic targets for HCC treatment by exploring TIC oncogenesis.

Main Methods:

• This review synthesizes existing research on HCV, TICs, and HCC.
• It analyzes the mechanisms by which HCV promotes TIC formation and subsequent HCC development.
• The review identifies key oncogenic pathways and hallmarks of TICs as potential therapeutic targets.

Main Results:

• HCV infection plays a crucial role in the transformation of liver cells and the generation of TICs.
• TICs are central to HCC development and confer resistance to conventional therapies.
• Ten specific hallmarks of TIC oncogenesis in HCC have been identified as potential therapeutic targets.

Conclusions:

• HCV-driven HCC development is closely associated with the emergence of TICs.
• Understanding the role of TICs in HCV-associated HCC provides a promising avenue for novel therapeutic strategies.
• Targeting the identified hallmarks of TIC oncogenesis presents a potential strategy for overcoming therapeutic resistance in HCC.